Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Remedy for nerve damage

A technique for nerve damage and therapeutic agents, applied in the field of therapeutic agents for nerve damage, capable of solving problems such as non-disclosure or prompting

Inactive Publication Date: 2006-06-28
SEIKAGAKU KOGYO CO LTD
View PDF2 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] However, there is no disclosure or suggestion about the use of low molecular weight carbohydrates (particularly low molecular weight HA) consisting of at least glucuronic acid (GlcA) and / or N-acetylglucosamine (GlcNAc), so there is no disclosure or suggestion of such Low-molecular-weight sugars bring better effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Remedy for nerve damage
  • Remedy for nerve damage
  • Remedy for nerve damage

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0071] Embodiments of the present invention will be specifically described below. However, the scope of the present invention is not limited thereto.

[0072]

[0073] First, substances and the like used in these examples will be described.

[0074] Reagents, etc.

[0075] Low-molecular-weight HA is used as a low-molecular-weight saccharide composed of at least GlcA and / or GlcNAc.

[0076] HA from Seikagaku Corporation was used as the low molecular weight HA. The low molecular weight HA has the following structure and has the following characteristics (abbreviations used in this example are shown in brackets below. In the following formulae, the symbol "-" represents a glycosidic bond.).

[0077] Saturated HA tetrasaccharide (hereinafter referred to as "HA4").

[0078] GlcA-GlcNAc-GlcA-GlcNAc

[0079] According to the method described by Nagasawa et al. (Carbohyd. Res., 141, p99-110, 1985), HA4 was obtained by size fractionation of degradation products prepared by anion...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The object of the present invention is to provide a therapeutic agent for nerve damage caused by spinal cord injury, nerve trauma, etc., which contains low molecular weight sugars as active ingredients. The low molecular weight sugars include at least glucuronic acid and / or N-acetylglucosamine. As constituent sugars or pharmaceutically acceptable salts thereof. Preferably, the nerve damage treatment agent contains low molecular weight hyaluronic acid (further preferably hyaluronic acid disaccharide to hyaluronic acid 2500 sugar, further preferably hyaluronic acid disaccharide to hyaluronic acid 50 sugar, particularly preferably hyaluronic acid tetrasaccharide ) or a pharmaceutically acceptable salt thereof as the active ingredient.

Description

technical field [0001] The present invention relates to a therapeutic agent for nerve damage, which contains low-molecular-weight saccharides as active ingredients, and at least glucuronic acid and / or N-acetylglucosamine (particularly, low-molecular-weight hyaluronic acid) are contained in the composition of the low-molecular-weight saccharides. acid) or a pharmaceutically acceptable salt thereof. Background technique [0002] JP11-140103A discloses an aqueous solution comprising hyaluronic acid (HA) or a pharmaceutically acceptable salt thereof for spinal cord perfusion, which describes that the perfusion solution is useful for spinal cord perfusion treatment of spinal cord injury. In addition, HA with an average molecular weight of 500,000 to 4,000,000 is exemplified in the document. [0003] However, there is no disclosure or suggestion about the use of low molecular weight carbohydrates (particularly low molecular weight HA) consisting of at least glucuronic acid (GlcA)...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/70A61K31/726A61K31/728A61P25/00C07H5/06C07H7/033C08B37/08
CPCA61K31/70A61K31/726A61K31/728C07H5/06C07H7/033C08B37/0072A61P19/00A61P25/00A61P25/02A61P25/28
Inventor 加藤忠彦浅利晃
Owner SEIKAGAKU KOGYO CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com